pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
GILEAD SCIENCES INC · news · pharmadog
← back to GILEAD SCIENCES INC
News mentioning GILEAD SCIENCES INC
84
stories
13h
First U.S. bird flu death of the year after cattle exposure
stat
1d
STAT+: FDA OKs generic HIV prevention shot, widening access for lower-income countries
stat
1d
Vistagen cuts workforce for second time in 2026
biospace
5d
Gilead reveals partial clinical hold on 2 CAR-T cell therapy trials
fiercebiotech
5d
Biopharma cuts at manufacturing plants expected to affect 4,000+
biospace
7d
Parkinson’s-focused Aspen and bispecific biotech Bambusa both shoot for $134M IPOs
fiercebiotech
8d
Another autoimmune CAR-T death; Treasury zeroes in on China deals
biopharma dive
11d
Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar
biospace
11d
ESMO 2026: Marengo's bispecific antibody shrinks 8 tumor types in Phase 2
biospace
11d
Gilead to pay $1.3B upfront for PepStar’s oral IL-23 challenger to J&J’s Icotyde
fiercebiotech
12d
Gilead strikes $1.3B upfront China deal for oral IL-23 drug
endpoints
12d
STAT+: Gilead to pay $45 million to settle kickback charges filed by Texas attorney general
stat
12d
GSK, Ionis hepatitis B functional cure breaks open market for followers
biospace
12d
ESMO 2026: Merck’s Kelun-partnered ADC hits the ‘Goldilocks zone,’ VP says
biospace
13d
The 6 biggest crossover rounds in biopharma history
biospace
14d
Gilead’s ‘highly competitive’ mid-stage ulcerative colitis data ‘validate’ I&I push
biospace
15d
Gilead’s pill posts stronger colitis remission rates than Entyvio
endpoints
15d
STAT+: Gilead’s IBD drug eliminated symptoms for patients, mid-stage study finds
stat
19d
Belgian startup revives Galapagos CAR-T research
biopharma dive
19d
Stoffels strikes up new biotech in return to Galapagos cell therapy mission
biospace
19d
Rebranded Galapagos finally finds buyer for unwanted cell therapy pipeline
fiercebiotech
20d
Gilead snags equity stake in Vir with up to $1.87B deal for three T cell engagers
biospace
20d
J&J earnings set ‘negative tone’; Shkreli vs. the FTC
biopharma dive
20d
Vir makes solid tumor T cell engager deal with Gilead
endpoints
21d
Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEs
fiercebiotech
24d
Parkinson’s-focused Aspen and bispecific biotech Bambusa plan IPOs
fiercebiotech
25d
Viking commercial chief is out in a hurry; Gilead looks to BeOne exec for China expansion
endpoints
28d
BioSpace 40 Under 40 winners make their mark on biopharma
biospace
Oct 2, 26
Novartis wagers almost $8B on a Chinese biotech’s RNA drugs
biopharma dive
Sep 28, 26
Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Vir
fiercebiotech
← prev
page 1 of 3
next →
